IE
CPRX

Israel Englander’s Catalyst Pharmaceutical CPRX Stock Holding History

Israel Englander’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-146,500
Closed -$2.89M – 6075
2025
Q3 		$2.89M Buy
+146,500
New +$3.01M ﹤0.01% 3706

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Israel Englander's CPRX Position: Q2 2026 in Review

Israel Englander increased its Catalyst Pharmaceutical (CPRX) stake by 39% in Q2 2026, buying an estimated $8.91M and bringing the position to 1,068,724 shares worth $33.6M. The position accounts for 0.01% of the portfolio, ranked #1188.

Israel Englander first reported a position in CPRX in Q3 2014 and has held it in 43 quarters since. The position peaked at $43M in Q4 2022. 392 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Israel Englander held 1,068,724 shares of Catalyst Pharmaceutical worth $33.6M as of Q2 2026.
  • Israel Englander bought 301,733 Catalyst Pharmaceutical shares in Q2 2026, an estimated $8.91M.
  • Catalyst Pharmaceutical made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1188 holding.
  • Israel Englander first reported a position in Catalyst Pharmaceutical in Q3 2014 and has held it in 43 quarters since.
  • Israel Englander's Catalyst Pharmaceutical position peaked at $43M in Q4 2022.
  • 392 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.